Floatz logo

AMSACRINE

Leukemia

Universitätsklinikum Hamburg-EppendorfSmall moleculePhase 3Dormant
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
70/ 100
Competitive Position
65/ 100

Competitive context

125 Active assets in the Leukemia cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
Inhye Ahn
Phase 3BB
PEGASPARGASE
Dana-Farber Cancer Institute
Phase 3BB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 4BB
ASPARAGINASE
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 3BB
Idarubicine
Affiliated Hospital of Nantong University
Phase 3BB

View all 50 →

Same molecule, other indications

AMSACRINE is also rated in:

acute myeloid leukemiaDormant
BBB
Indicative ·
75 / 100
View asset →
Acute Myeloid LeukemiaDormant
BB
Indicative ·
64 / 100
View asset →
myelodysplastic syndromeDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →